We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 8 June 2021, highlighting Roche data presented at the ASCO21 Virtual Scientific Program June 4 – 8 2021.
16:00 – 17:30 CEST / 15:00 - 16:30 BST
10:00 – 11:30 am EDT / 7:00 – 3:30 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. > click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via > ir.roche.com
|
Best regards,
Karl Mahler
Head of Investor Relations
|
Sabine Borngräber
Investor Relations Officer
|
Roche Investor Relations | |
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
| Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com |
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
| Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com |
| |
Investor Relations North America | |
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com | Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com |
